Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin Renal Hemodynamics in ADPKD
NCT02511418Completed
- Sponsor
- Mayo Clinic
- Primary completion
- Jan 2007
- Modality
- Small Molecules
01
Overview
Open-label trial of simvastatin in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Effect of short term HMG-CoA reductase treatment at 4 weeks. Status: completed.
02
Drugs
simvastatin
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT02511418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511418.